Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | OMO-1 |
| Trade Name | |
| Synonyms | JNJ-38877618|OMO1 |
| Drug Descriptions |
OMO-1 (JNJ-38877618) is a MET inhibitor that suppresses the kinase activity of wild-type and mutant MET, potentially resulting in reduced tumor growth (Cancer Res 2018;78(13 Suppl):Abstract nr 4791). |
| DrugClasses | MET Inhibitor 59 |
| CAS Registry Number | 943540-74-7 |
| NCIT ID | C148537 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Erlotinib + OMO-1 | Erlotinib OMO-1 | 0 | 0 |
| OMO-1 | OMO-1 | 0 | 1 |
| OMO-1 + unspecified EGFR tyrosine kinase inhibitor | OMO-1 unspecified EGFR tyrosine kinase inhibitor | 0 | 1 |